Evogene Ltd
NASDAQ:EVGN
Evogene Ltd
NASDAQ:EVGN
Price:
0.838
USD
-1.11%
Market Closed
Market Cap:
$7.3m
Relative Value
The Relative Value of one
EVGN
stock under the Base Case scenario is
0.976
USD.
Compared to the current market price of 0.838 USD,
Evogene Ltd
is
Undervalued by 14%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EVGN
Relative Value
Base Case
0.976
USD
Undervaluation 14%
Multiples Across Competitors
EVGN Competitors Multiples
Evogene Ltd Competitors
Evogene Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
|
Evogene Ltd
NASDAQ:EVGN
|
7.3m USD | 1.4 | -2.7 | 0.6 | 0.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.4B USD | 6.7 | 97.8 | 16 | 22.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.3B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.1B USD | 6.1 | 21.1 | 13.2 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.8B USD | 9.8 | 29.6 | 22.3 | 23.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81B USD | 5.6 | 18 | 13.4 | 15.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69.8B AUD | 3.2 | 35.6 | 11.7 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.7B EUR | 10.9 | 35.1 | 38.1 | 38.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
